The gold price has climbed to a two-month high of $1,825/oz. Despite the recent uptick gold is still 10% below its all-time high of summer 2020. As Myra Saefong notes in Barron’s, 2021 is set to be the metal’s first losing year since 2018. Its recent “drubbing” is perplexing, says John Authers on Bloomberg. Conditions over the last year should have boosted gold, which does best at times of high inflation (check) and monetary debasement (check). Instead, gold-mining stocks have been the worst-performing sector in the S&P 500 over the last year. Still, something might be about to shift. The ratio of US stocks to gold is running at a 16-year high, more proof, if any were needed, that American stocks are historically overpriced.
Gold bulls had been betting on widespread “revulsion” for paper currencies in the wake of massive money-printing by central banks, says Randall Forsyth in Barron’s. That revulsion has come, but it seems to have boosted cryptocurrencies (dubbed “digital gold”) rather than gold. “Fans of gold…arguably are the most contrary investors” and, at present, “perhaps the loneliest”.
Gold got carried away during the 2018-2020 bull run, says Eoin Treacy of Fuller Treacy Money. After a 75% jump it became overheated in summer last year. Still, this correction may be nearing its end after 18 months, “it is a good time to start looking at the sector again”.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Which platforms will offer crypto ETNs?Crypto ETNs will soon once again be available to UK investors. We reveal the investment platforms planning to offer them to customers.
-
Healthcare stocks look cheap, but tread carefullyShares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?
-
Healthcare stocks look cheap, but tread carefully
Shares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?
-
The Palace of Westminster is falling downThe Palace of Westminster is in need of repair, but the bill is prohibitive, says Simon Wilson
-
'It’s time to buy British equities'Opinion There is no better place to start investing in UK equities than with two of MoneyWeek’s favourite investment trusts, says Max King
-
Sotheby’s fishes for art collectors – will it succeed?Sotheby’s is seeking to restore confidence in the market after landing Leonard Lauder's art collection, including Gustav Klimt's Portrait of Elisabeth Lederer
-
How to cash in on overlooked British bargains offering both income and growthOpinion Sue Noffke, manager of the Schroder Income Growth Fund, selects three UK stocks where she’d put her money
-
Beazley: a compelling specialist insurerThe insurer Beazley is unusually profitable at present, and that looks set to continue. The stock is also a valuable portfolio diversifier, says Jamie Ward
-
The problem with renewables trustsThe value of assets owned by renewables trusts is far more volatile than investors expected
-
To hedge or not to hedge, that is the questionThe mechanics of hedging are very logical, but deciding when to add a hedge is rarely a simple decision
